
















S12Congenital Disorders of Ribosome Biogenesis
and Bone Marrow Failure
Kathleen M. Sakamoto,1 Akiko Shimamura,2 Stella M. Davies3Diamond Blackfan anemia (DBA) is a congenital bone marrow (BM) failure syndrome that typically results in
macrocytic anemia within the first year of life. DBA is also associated with birth defects, increased incidence
of cancer, and other cytopenias. Shwachman-Diamond syndrome (SDS) is a multisystem disease character-
ized by exocrine pancreatic dysfunction, impaired hematopoiesis, and leukemia predisposition. Other clinical
features include skeletal, immunologic, hepatic, and cardiac disorders. Treatment for these BM failure syn-
dromes, including stem cell transplantation (SCT), will be discussed in this review.
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PATHOGENESIS OF DIAMOND BLACKFAN
ANEMIA (DBA): KATHLEEN SAKAMOTO
Diamond Black Anemia (DBA) is an inherited hy-
poplastic anemia that usually presents in early infancy
and was first described by Josephs, Diamond and
Blackfan in the 1930s [1,2]. DBA is 1 of a group of ge-
netic disorders referred to as ‘‘inherited bone marrow
failure syndromes’’ [3]. The incidence of DBA is ap-
proximately 5 per million live births. DBA consists of
bone marrow (BM) failure, birth defects, and a predis-
position to develop malignancies [3]. The hematopoi-
etic defect is characterized by progressive apoptosis of
erythroid precursors, resulting in normochromic or
macrocytic anemia. DBA is also associated with cra-
niofacial, thumb, cardiac, and urogenital malforma-
tions [1]. Other hallmarks of the disease include
reticulocytopenia, normocellular BM with decreased
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ity [3]. The presence of macrocytosis, elevated adeno-
sine deaminase, and increased fetal hemoglobin levels
suggests that the phenotype of DBA is secondary to
‘‘stress erythropoiesis’’ (Table 1) [3].
The reasons for the clinical presentation of DBA
soon after birth may because of decreased erythropoie-
tin production, elevated hemoglobin level, and the
switch to decreased O2-affinity adult hemoglobin
allowing for more oxygen delivery to tissues [3]. There
are also data suggesting that erythroid progenitors are
less sensitive to erythropoietin in the transition from
fetal state to the adult state [3]. Furthermore, anemia
results from a defect in erythropoiesis, rather than
immune-mediated destruction [3]. BM from DBA pa-
tients demonstrated decreased formation of either early
or late erythroid colony formingunits anddefective ery-
throid differentiation [3].More recent data suggest that
there is premature apoptosis of erythroid progenitors
[3,4] in mammalian and zebrafish models [4,5].
In 1999, the first DBA gene was identified as being
ribosomal protein subunit 19 (RPS19) (Table 1) [6,7].
Studies have demonstrated heterozygosity for muta-
tions in RPS19 in 24% of patients [8]. In 2006, another
DBA gene was recently identified as ribosomal protein
24 (RPS24) [7,9]. Since then,mutations in several other
ribosomal proteins of the 40S ribosomal subunit
(RPS17, RPS19, and RPS24) and the 60S ribosomal
subunit (RPS5, RPL11, and RPL35A) [3,10,11].
More recently, Ebert et al. [12,13] reported that
patients with myelodysplastic syndrome (MDS) and
5q- have haploinsufficiency of RPS14. This further
supports the notion that insufficiency of ribosomal sub-
units contributes to erythroid failure.The consequence
of RPS mutations is abnormal ribosomal biosynthesis.
Table 1. Genes involved in DBA and SDS












DBA indicates Diamond Blackfan anemia; SDS, Shwachman-Diamond
Syndrome.
*Currently, ranges for SDS have not been established in commercial labs.
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ticularly vulnerable to ribosome deficiency.
The precise role of RPS19 haploinsufficiency in
the pathogenesis of DBA is not completely under-
stood. The fact that DBA presents early in life suggests
that RPS19 affects erythropoiesis early during devel-
opment and alterations in blood cell production at
birth activates specific pathways that lead to the
erythroid phenotype [14]. To test this possibility,
a zebrafish model of RPS19 deficiency was generated
by injecting RPS19 morpholinos in embryos [4]. The
embryos had developmental abnormalities very similar
to humans, including craniofacial abnormalities, short
fins, and defective erythropoiesis. Furthermore, ery-
throid progenitors were macrocytic and underwent
premature apoptosis (Figure 1) [4].
Knockout of RPS19 in mice is embryonic lethal
and heterozygotes lack a DBA phenotype [14].
RPS19 knockdown in mouse erythroleukemia cells
resulted in G0/G1 arrest and increased expression of
p21 and p27 and decreased expression of the anti-
apoptotic proteins, Bcl-2 and Bad [15]. CD341 cells
from DBA patients undergo apoptosis in in vitro
culture assays [15]. Recently, gene therapy in CD341
cells from DBA patients with RPS19 mutations wasFigure 1. DBA phenotype in zebrafish embryos injected with RPS19morpholi
embryos injected with RPS19 morpholinos and there are only few cells in the
embryos per group. (C) Erythroid cells from the blood of a morphant embryo
differ frommammalian cells in that both primitive and definitive cells are nucleat
representative of 6 to 10 embryos. (D) The level of hemoglobin is lower in mor
research was originally published as DanilovaN, SakamotoKM, Lin S. Ribosoma
and defective erythropoiesis through activation of p53 protein family. Blood. 2shown to rescue the erythroid phenotype in mouse
transplantation models [16].
There is strong evidence that erythroid defects due
to RPS19 haploinsufficiency may be regulated at least
in part, through p53-dependent pathways. Previous
studies demonstrated that disruption of the nucleolus
or genotoxic stress results in p53 upregulation [17].
Haploinsufficiency of RPS6 and RPL22 have also
been shown to lead to activation of p53 [4,18,19].
More recently, rps19 and rps20 genes were found to
be mutated in mice with a dark skin phenotype [20].
The phenotype of the rps19mutant inmice was similar
to DBA, including apoptosis of erythroid progenitor
cells and growth retardation [3,20]. One simple expla-
nation for the erythroid phenotype is that RPS19
activates stress-related pathways, resulting in p53
upregulation and induction of apoptosis of erythroid
progenitors. However, it is more likely that the mech-
anism is more complicated, including activation of
p53-independent pathways, which might affect ery-
throid specific differentiation pathways. Thus, the pre-
cise regulation of p53 downstream of RPS deficiency is
still unknown.
DBA is characterized by heterogeneity in both clin-
ical presentation and response to treatment. At this
time, phenotypic and genotypic correlation to predict
response to treatment has not been identified. DBA is
also considered a cancer predisposition syndrome. In
a recent review by Lipton and Ellis [21], of the 30 cases
of cancer in DBA patients, 15 were hematopoietic ma-
lignancies. Although cancer is rare, the incidence is
higher than what would be expected for the specific
age group [21]. The prognosis is poor in DBA patients
with cancer, mostly because of significant myelosup-
pression following chemotherapy [21].
The treatment of DBA consists of corticosteroids
and red cell transfusions [1,3]. Studies in the 1950s
demonstrated that steroids could improve anemia in
DBA patients, despite the fact that DBA is not annos. (A,B) At 72 high-power field, there are fewer blood cells in zebrafish
heart region: 2.5 ng morpholino per embryo, O-dianizidine staining, 30
are variable in size; some look like erythroblasts. Zebrafish erythrocytes
ed. Blood smears were prepared from individual embryos; the results are
phants at day 5 in dependence with morpholino dose [4]. This figure and
l protein S19 deficiency in zebrafish leads to developmental abnormalities
008;112:5228-5237. Q American Society of Hematology.
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given to DBA patients with daily subcutaneous admin-
istration of the iron chelator, deferoxamine. Previous
literature has reported that 79% of patients were re-
sponsive to steroids, 27% were nonresponsive, and
4% were never treated [1,3]. More recent data from
the DBA registry demonstrated that 37% of patients
receive corticosteroids and 31% receive red cell trans-
fusions. Of the 35% ofDBA patients who were not ste-
roid responsive, 22% became steroid refractory after
a period of time, and 33% could not be weaned to an
acceptable dose [3]. Steroid treatment is often delayed
until after 1 year of age to minimize effects on growth
and development. Patients who do not respond within
a month of starting steroid therapy are considered
refractory and require red cell transfusions [3]. Remis-
sions have been described with DBA patients; how-
ever, there are few data on the percentage of patients
who were able to sustain red cell production for over
6months without therapy [1,3].With increased under-
standing of the molecular pathogenesis of DBA and
the role of ribosomal biogenesis, there is potential
for new therapeutic approaches to treat these patients
in the future.SHWACHMAN DIAMOND SYNDROME (SDS):
CLINICAL AND MOLECULAR FEATURES:
AKIKO SHIMAMURA
Shwachman Diamond Syndrome (SDS) is an au-
tosomal recessively inherited syndrome characterized
by BM failure, exocrine pancreatic dysfunction, and
leukemia predisposition (reviewed in [22]). The most
common manifestation of BM failure is neutropenia.
Patients may also develop thrombocytopenia and ane-
mia. A subset of patients progress to severe aplastic
anemia (SAA). Erythroid macrocytosis and elevated
fetal hemoglobin levels may be present. Clonal cytoge-
netic abnormalities frequently arise in the bone mar-
row [23]. Patients with SDS are at increased risk for
myelodysplastic sydrome (MDS) and acute myeloge-
nous leukemia (AML) [24,25].
Histologic data regarding the exocrine pancreas are
limited. Much of the pancreatic tissue is replaced with
fat amid a paucity of acini. The pancreatic ducts and is-
lets appear intact. Pancreatic atresia with lipomatosis
may be evident on imaging studies. If the pancreatic in-
volvement is severe, patients may be symptomatic with
steatorrhea, fat-soluble vitamin deficiency, and failure
to thrive.Many patients lack clinical symptoms or their
symptoms may resolve over time. Tests for exocrine
pancreatic dysfunction include low pancreatic elastase,
low serum trypsinogen, and low pancreatic isoamylase
levels (Table 1) [26].
Additional clinical features have also been described
forSDS. Skeletal abnormalities are commonlyobserved[27,28]. Skeletal findings include metaphyseal dysosto-
sis, thoracic dystrophies, and low bone turnover osteo-
penia. Hepatomegaly with elevated transaminases may
present in infancy. These hepatic abnormalities typi-
cally resolve spontaneously with age. An eczematous
rash is also frequently reported in infancy. Patients
may have immunologic compromise such as low immu-
noglobulin levels and reduced B andT cell number and
function [29]. Cardiac, neurologic, and endocrine ab-
normalities have also been described.
Over 90% of patients with SDS harbor biallelic
mutations in theSBDS (Shwachman-Bodian-Diamond
Syndrome) gene, which encodes a highly conserved,
ubiquitously expressed protein [30]. Sbds2/2mice ex-
hibit early embryonic lethality [31]. The SBDS protein
is localized throughout the cell and shuttles in and out
of the nucleolus, the major cellular site of ribosome
biosynthesis [32]. Mammalian SBDS binds to the 60S
large ribosomal subunit [33]. Several screens for
SBDS-associated proteins have identified ribosomal
proteins and assembly factors [33-36]. Knockdown of
the yeast orthologue, Sdo1, results in a slow growth
phenotype, which is suppressed by mutations in Tif6
[37]. Tif6 is a ribosome assembly factor thatmust be re-
leased from the 60S subunit to allow the joining of the
40S and 60S ribosomal subunits into themature 80S ri-
bosome. Tif6 suppressor mutations result in dimin-
ished binding of Tif6 to the 60S ribosomes. Based on
these data, a model has been proposed, whereby Sdo1
promotes the dissociation of Tif6 to allow the joining
of the 40S and 60S ribosomal subunits [37]. Thus, in
contrast to the situation in DBA where loss of ribo-
somal subunit proteins impairs the formation of the
40S or 60S precursor subunit, SBDS functions at a later
stage of ribosome biogenesis after the 40S and 60S sub-
units have been assembled.
SBDS has also been implicated in additional cellu-
lar functions that likely also contribute to the clinical
phenotype. SBDS functions in mitotic spindle dynam-
ics by promoting spindle stabilization [38]. SBDS loss
also affects actin polymerization [39] and neutrophil
chemotaxis [40]. SBDS has also been implicated in
cellular stress responses [41].
The diagnosis of SDS is easily missed because
cytopenias may be mild or intermittent and exocrine
pancreatic dysfunction may be asymptomatic. The
full clinical phenotypic spectrum for SDS is poorly un-
derstood. Most studies describing the SDS phenotype
were conducted prior to the advent of genetic testing.
Diagnosis is further complicated by the finding that
around 10% of SDS patients lack identifiable SBDS
mutations [30]. Because SDS is an autosomal reces-
sively inherited disorder, all siblings of an SDS
proband should also be tested.
The only curative treatment for BM failure in SDS
is a hematopoietic stem cell transplant (HSCT); how-
ever, patients with SDS are at increased risk for
Biol Blood Marrow Transplant 16:S12-S17, 2010 S15Congenital Disorders of Ribosome Biogenesistransplant regimen-related toxicity as discussed later.
Neutropenia often responds to granulocyte-colony
stimulating factor (G-CSF). Coagulopathy may result
from thrombocytopenia or from vitamin K deficiency
secondary to pancreatic insufficiency. Treatment of
coagulopathy includes platelet transfusions, and vita-
min K supplementation. Treatment of active bleeding
with antifibrinolytic agents such as aminocaproic acid
may also be considered as clinically indicated. Symp-
tomatic or severe anemia is treated with red cell trans-
fusions.The clinicalmanagement of cytogenetic clones
arising in the BM must be considered within the con-
text of the BM morphology, the peripheral blood
counts, and the specific cytogenetic findings. HSCT
should be considered for MDS or AML arising in pa-
tients with SDS, although data are lacking regarding
optimal treatment regimens. Because patients with
SDS are at increased risk for hematologic malignan-
cies, regular monitoring of the blood counts and BM
are recommended [42].STEM CELLTRANSPLANTATION FOR
DISEASE WITH RIBOSOMAL DEFECTS:
STELLA DAVIES
Transplant For DBA
Experience with transplantation for DBA is lim-
ited, as the majority of children can be managed with
a combination of steroids and transfusion with or with-
out chelation. Steroid nonresponsiveness and high
transfusion needs with associated iron overload is the
most frequent indication for the procedure in those
children who have been transplanted. The careful
identification of children most likely to benefit from
transplantation is 1 of the most important challenges
that continually needs to be addressed, as outcomes
of transplant improve, a change that must be balanced
against parallel advances in chelation that can improve
supportive therapy.
Several registry series published in the last 5 years
have indicated that reasonable outcomes can be
obtained for children with DBA receiving transplant
from an HLA-matched sibling donor, Roy et al. [43]
described outcomes of 61 transplants for DBA
reported to the Center for International Blood and
Marrow Transplant Research (CIBMTR). Sixty-seven
percent of cases (n5 41) received stem cells from
a matched related donor, median age was 7 years
(range: 1-32 years), and the majority of cases (.64%)
had received .20 prior transfusions. Day 100 mortal-
ity was significant at 18%, and survival at 3 years was
64%. Survival was significantly reduced in recipients
of alternative donor grafts (unrelated [n5 12] or mis-
matched family member [n5 8]) compared with sib-
ling donor grafts (76% versus 39%; P5 .005). In
addition, 3-year survival was lower in recipients witha reduced Karnofsky performance score (KPS) (42%
KPS \90% versus 75% KPS .90%; P5 .011),
suggesting that outcomes are improved with earlier
transplant as might be expected. This study offers
the largest series of transplanted DBA cases yet, but
as a registry series is necessarily limited by few details
regarding the rationale in selecting transplantation for
individual patients.
The DBA registry, that now includes more than
420 patients, updated their results in 2006, describing
transplant outcomes in 15 alternative donor graft re-
cipients (2 mismatched related, 4 unrelated cord blood
[CB], 8 unrelated BM, and 1 unrelated peripheral
blood stem cell [PBSC]) and 21 sibling donor recipi-
ents [44]. Outcomes in this report were similar to those
reported by CIBMTR (survival 72% for sibling graft
recipients versus 19% for alternative donor recipients),
and it is likely that there may be significant overlap of
cases between the 2 reports. The majority of patients
were selected for transplant because of transfusion de-
pendence, although 2 cases had SAA, and 1 significant
thrombocytopenia.
The AA committee of the Japanese Society of Pedi-
atric Hematology has reported outcomes of 19 trans-
plants (13 matched siblings, 6 alternative donors) for
DBA in Japan [45]. All the patients in this series had
been extensively transfused, and many reported signifi-
cant toxicities from steroids. In this series, all the chil-
dren who received BM as a stem cell source (either
from a sibling or an unrelated donor) were surviving.
In contrast, none of the 3 unrelated CB recipients sur-
vived, although 2 sibling CB recipients were alive and
free of disease. The authors of this study suggest that
BMmight be preferred over CB for childrenwithDBA.
The disappointing results of transplantation from
alternative donors in these reports may reflect ad-
vanced disease at time of transplant, or may be a conse-
quence of the transplants strategies applied. The
majority of recipients of alternative donor grafts
received a total body irradiation (TBI)-based prepara-
tive, regimen, whereas the majority of sibling donors
did not.Ostronoff et al. [46] have described a successful
sibling donor transplant in an infant with DBA using
a nonmyeloablative (NMA) preparative regimen
(200 cGy TBI and 90 mg/m2 fludarabine [Flu]), and
is possible that reduced intensity conditioning (RIC)
orNMA strategies could improve outcomes of alterna-
tive donor grafts. Preimplantation genetic diagnosis
has been used to identify embryos that are unaffected
with DBA and are HLA-matched with an affected
child, to make available a matched donor for a transfu-
sion-dependent child [47]. The need for this compli-
cated and expensive approach will be obviated if
outcomes using unrelated stem cell sources are im-
proved. Investigators are also pursuing potential gene
therapy approaches, and have shown that RPS19
gene transduction can correct the defect in erythroid
S16 Biol Blood Marrow Transplant 16:S12-S17, 2010K. M. Sakamoto et al.development in a murine model [16]. Additional work
to develop safe vectors for clinical use will be needed
before clinical trials can start in children with DBA.Transplant For SDS
Children with SDSmay be candidates for transplan-
tation because of progressive cytopenias, or evolution to
myeloid malignancy (MDS or AML). Development of
clonal hematopoiesis necessarily causes anxiety, al-
though caution should be used in proceeding to trans-
plant for this indication alone. Cunningham et al. [48]
reported isochromosome 7q in 8 children with SDS.
Three children were transplanted and only 1 survives,
whereas the untransplanted children are all surviving
without evidenceof progression toMDSorAML.These
authors suggest that isochromosome7qhas a specific and
benign clinical history in persons with SDS and alone
should not be considered an indication for transplant.
Early reports of transplantation for SDS have iden-
tified significant toxicities, including an excess of car-
diac toxicity, likely related to the underlying disease
[49]. The largest reported series of transplants comes
from the European Group for Blood and Marrow
Transplantation, who described 26 transplants, 19
using unrelated donor stem cells, 6 sibling donor
stem cells, and 1 other graft [50]. Treatment-related
mortality (TRM) was high at 35%, with a follow-up
of 1.1 years, whereas overall survival (OS) was
64.5%. Most of the fatal toxicity was because of organ
failure and infections secondary to the preparative reg-
imen. These data are similar to those reported by the
French neutropenia registry describing 60% event-
free survival (EFS) in 10 transplant recipients (6 sibling
donors, 4 unrelated donors) [51].
RIC has been investigated in SDS with good out-
comes, at least in early reports. Bhatla et al. [52] de-
scribed 7 patients treated with RIC chemotherapy
(Campath, Flu, and melphalan [Mel]; 4 sibling donors,
3 unrelated donors); all were surviving at the time of
report. Similarly, Sauer et al. [53] report 3 children
with SDS conditioned with Flu, treosulfan, and Mel
prior to transplant, 1 receiving cells from a sibling do-
nor, 1 unrelated donor, and 1 unrelated CB graft. Two
of the 3 children were alive at time of report. Taken to-
gether, these data provide encouraging evidence that
survival after transplant for SDS can be improved by
the use of RIC preparative regimens.ACKNOWLEDGMENTS
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